Table 1 Clinical and demographic characteristics of the study cohort (N = 123).
From: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Characteristics | Median | IQR |
|---|---|---|
WBC (×103/L) | 8 | 3.5–30.0 |
HGB (g/dL) | 9.1 | 8.5–10.0 |
PLT (×103/μL) | 55 | 29–86 |
BM blasts (%) | 46 | 30–67 |
PB blasts (%) | 27 | 5–57 |
LDH (U/L) | 689 | 478–1154 |
Age (y) | 61 | 52–73 |
No. | % | |
Ontogeny | ||
De novo | 93 | 76 |
Secondary/therapy related | 30 | 24 |
Prior treatment | ||
Untreated | 88 | 72 |
Treated | 35 | 28 |
Karyotype | ||
Normal karyotype | 91 | 74 |
Complex karyotype | 12 | 10 |
Others | 20 | 16 |
Treatment | ||
IA-based chemotherapy | 49 | 40 |
AraC-based chemotherapy | 12 | 10 |
decitabine and venetoclax | 27 | 22 |
HMA without venetoclax | 24 | 20 |
Others | 11 | 9 |
Sex | ||
Female | 48 | 39 |
